Overview

• YCT-529 is the first oral non-hormonal male contraceptive that targets retinoic acid receptor alpha to halt sperm production without affecting testosterone or libido
• Phase I single-dose study in 16 vasectomized men showed no serious adverse events, stable hormone levels and blood exposure matching effective animal doses
• Preclinical trials in mice and nonhuman primates demonstrated 99% efficacy in preventing pregnancy with full fertility restoration after discontinuation
• Ongoing repeat-dose trials are assessing daily administration for 28 days and 90 days to monitor sustained safety and impact on sperm parameters
• YourChoice Therapeutics is preparing larger Phase II studies to determine optimal dosing regimens and move toward market approval